医学
临床试验
食品药品监督管理局
乳腺癌
癌症
抗体-药物偶联物
临床研究
药品
肿瘤科
抗体
免疫学
生物信息学
癌症研究
药理学
单克隆抗体
内科学
生物
作者
Pasquale Lombardi,Marco Filetti,Rosa Falcone,Valeria Altamura,Francesco Paroni Sterbini,Emilio Bria,Alessandra Fabi,Diana Giannarelli,Giovanni Scambia,Gennaro Daniele
出处
期刊:Cancers
[MDPI AG]
日期:2023-03-13
卷期号:15 (6): 1744-1744
被引量:9
标识
DOI:10.3390/cancers15061744
摘要
Trophoblast cell surface antigen-2 (Trop-2) is a glycoprotein that was first described as a membrane marker of trophoblast cells and was associated with regenerative abilities. Trop-2 overexpression was also described in several tumour types. Nevertheless, the therapeutic potential of Trop-2 was widely recognized and clinical studies with drug–antibody conjugates have been initiated in various cancer types. Recently, these efforts have been rewarded with the approval of sacituzumab govitecan from both the Food and Drug Administration (FDA) and European Medicines Agency (EMA), for metastatic triple-negative breast cancer patients. In our work, we briefly summarize the various characteristics of cancer cells overexpressing Trop-2, the pre-clinical activities of specific inhibitors, and the role of anti-Trop-2 therapy in current clinical practice. We also review the ongoing clinical trials to provide a snapshot of the future developments of these therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI